Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Investing.com - Canaccord Genuity has reiterated its Buy rating and $75.00 price target on Exact Sciences (NASDAQ:EXAS), currently trading at $52.21, ahead of the company’s upcoming BLUE-C study data readout. The company, with a market capitalization of $9.85 billion, has seen three analysts revise their earnings estimates upward, with price targets ranging from $54 to $90.
The investment firm will host a virtual webcast panel on Monday, July 21 at 1:30PM ET featuring two key opinion leaders to discuss Exact Sciences’ blood-based test for colorectal cancer screening. InvestingPro analysis shows the company achieving 11.57% revenue growth, with analysts predicting profitability this year. Get deeper insights with InvestingPro’s comprehensive research report, available for over 1,400 US stocks.
The panel will include Mark Hiatt, MD, MBA, MS, of Hiatt Advisory Services, and Dr. Francis Dailey of Kansas City Gastroenterology & Hepatology Physicians Group, LLC, who hold differing views on competing screening tests.
Exact Sciences aims to announce data from its prospective BLUE-C study in mid-summer, which will be compared to the performance of Guardant Health (NASDAQ:GH)’s Shield blood test results from the ECLIPSE study released in December 2022.
The panel will discuss expectations for the BLUE-C blood test data and potential implications for both Exact Sciences and Guardant Health under various performance scenarios.
In other recent news, Exact Sciences announced that its Oncodetect molecular residual disease test has received Medicare coverage for patients with specific stages of colorectal cancer. This coverage, granted through the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program, is applicable for up to five years and is seen as a significant milestone for the company. Following this development, Canaccord Genuity maintained its Buy rating on Exact Sciences, highlighting the long-term growth potential unlocked by the reimbursement decision. Additionally, Raymond (NSE:RYMD) James upgraded the company’s stock rating to Market Perform, noting the substantial market potential for the minimal residual disease market.
Exact Sciences also held its 2025 Annual Meeting, where shareholders approved a new Omnibus Long-Term Incentive Plan and an amendment to the Employee Stock Purchase Plan. These plans are intended to provide stock-based compensation and cash incentives to employees and directors. Furthermore, the company announced that it will release its second quarter 2025 financial results on August 6, 2025. Investors are keenly anticipating this release, with a webcast and conference call scheduled to discuss the results and business developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.